Nazartinib (EGF816) in patients with treatment-naive EGFR-mutant non-small cell lung cancer (NSCLC): Updated phase II results Meeting Abstract
| Authors: | Tan, D. S. W.; Leighl, N. B.; Yang, J. C. H.; Riely, G. J.; Sequist, L. V.; Toyozawa, R.; Wolf, J.; Felip, E.; Kim, S. W.; Aix, S. P.; Smit, E. F.; Hida, T.; Grohe, C.; Ghebremariam, S.; O'Sullivan-Djentuh, L.; Belli, R.; Giovannini, M.; Kim, D. W. |
| Abstract Title: | Nazartinib (EGF816) in patients with treatment-naive EGFR-mutant non-small cell lung cancer (NSCLC): Updated phase II results |
| Meeting Title: | 56th Annual Meeting of the American Society of Clinical Oncology (ASCO) |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 38 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2020 May 29-31 |
| Meeting Location: | Virtual Conference |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2020-05-20 |
| Language: | English |
| ACCESSION: | WOS:000560368303473 |
| PROVIDER: | wos |
| DOI: | 10.1200/JCO.2020.38.15_suppl.9574 |
| Notes: | Meeting Abstract: 9574 -- Source: Wos |
